The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | UNWOMEN
Aid agencies echoed wider warnings of growing signs of widespread starvation in Gaza on Tuesday, as UN-partnered international food security experts released their most dire assessment yet of the situation in the wartorn enclave.
1
1
1
Edited News | IOM , UNDP , UNHCR
Sudan: urgent help needed as more than 1.3 million war-displaced people begin to return home
As conflict rages on across parts of Sudan, pockets of relative safety have emerged in the past four month, spurring more than one million internally displaced Sudanese to make their way home, says the International Organization for Migration (IOM). A further 320,000 cross-border refugees have come back to Sudan since last year, mainly from Egypt and South Sudan, to assess the current situation before deciding to return to their country for good.
1
1
1
Edited News | UNRWA , WHO
Gaza: SOS messages describe people fainting from hunger; UN health worker detained
Worrying alerts from United Nations staff in Gaza who have been fainting from hunger and exhaustion over the past 48 hours have increased fears for people’s survival in the devastated enclave, UN humanitarians said on Tuesday.
1
1
1
Edited News | UNHCR , UNOG
Over 11.6 million refugees risk losing aid access due to funding cuts, says UNHCR
Approximately one in three refugees and other vulnerable individuals normally supported by the UN refugee agency (UNHCR) are expected to lose out from funding cuts, it said on Friday.
1
1
1
Edited News | OHCHR
Ravina Shamdasani, Spokesperson for the Office of the UN High Commissioner for Human Rights, made the following announcement on the Office’s opening of a new mission in Bangladesh.
1
1
1
Edited News | OHCHR
“The surge in the number of Afghans forced or compelled to return to Afghanistan this year is creating a multi-layered human rights crisis requiring the urgent attention of the international community,” UN Human Rights spokesperson Ravina Shamdasani said on Friday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Friday called for accountability and justice for the killings and other gross human rights violations and abuses in the southern city of Suweida.
1
1
1
Edited News | OHCHR , UNHCR
Syria: hundreds killed in Sweida, ‘widespread’ violations as civilians flee for their lives
Amid violent clashes in southern Syria’s Sweida governorate, a picture of grave human rights abuses and rising humanitarian needs is emerging by the hour, the UN said on Friday.
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press briefing in Geneva the UN Human Rights Spokesperson Liz Throssell made the following statement on the latest number of civilian casualties in Ukraine.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office on Tuesday called for investigations into hundreds of killings of Palestinians in the occupied West Bank by Israeli security forces and settlers, warning against ongoing forced mass displacement of the Palestinian population.
1
1
2
Edited News | OHCHR , UNRWA
Nearly 900 people have been killed in Gaza in recent weeks trying to fetch food, with most deaths linked to private aid hubs run by the Gaza Humanitarian Foundation (GHF), the UN human rights office, OHCHR, said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
The United Nations Integrated Office in Haiti (BINUH) and the UN Human Rights Office have today released a report detailing the evolution of violent gang incidents beyond the capital Port-au-Prince since October 2024 up to June 2025, and the resulting loss of life and mass displacement.